Andover

Researchers are evaluating two experimental medicines, freneslerbart and mevonlerbart, alone or combined as REGN-2Cat, in people with allergic conjunctivitis caused by cat hair or dander. The study aims to understand side effects and whether these medicines can reduce eye allergy symptoms compared to a placebo. It is a phase 3, randomized, double-masked, placebo-controlled trial sponsored by Regeneron Pharmaceuticals. Participants may receive freneslerbart, mevonlerbart, REGN-2Cat the combination, or placebo according to the study protocol. The study investigates different doses and combinations to monitor how much medicine is in the blood over time, the bodys immune response to the drugs, and the duration of the drug effects. The intervention is given during the treatment period, with assessments following conjunctival allergen challenges. Participants will have eye allergy symptoms assessed, including ocular itch and redness scores after allergen exposure. Researchers will also measure immune responses, drug levels in the blood, and monitor for side effects up to about 113 days. The study involves regular visits for testing, including skin prick tests and conjunctival allergen challenges, to evaluate treatment effects and safety throughout the trial duration.

Researchers are studying the safety and effectiveness of VSJ-110, an eye drop solution, compared to a placebo in treating dry eye. This phase 2 clinical trial aims to provide important information about how well VSJ-110 works and how safe it is for people with dry eye over an eight-week period. The study is randomized and double-masked, meaning neither participants nor researchers know who receives the treatment or placebo during the trial. Participants will be randomly assigned to receive either the VSJ-110 ophthalmic solution or a placebo solution. Both treatments are delivered as eye drops, and the study lasts for eight weeks. The trial is designed to closely monitor the participants response to treatment and any side effects that may occur during this time. Throughout the study, participants will attend scheduled visits where various assessments will be performed. These include measuring corneal staining, which shows eye surface damage, and performing Schirmers Tear Test to evaluate tear production. Participants will also report their eye dryness using a visual scale. The research team will monitor safety and collect data to evaluate the outcomes over the full eight weeks of treatment.

Researchers are studying the effects of over-the-counter lubricating eye drops on comfort, symptoms, and vision in adults with dry eye disease DED. This Phase 4 randomized study aims to compare the tolerability and visual outcomes of different preservative-free eye drops in people who have experienced dry eye symptoms for at least six months. The study focuses on evaluating how these products impact patient-reported symptoms and ocular surface health. Participants will be randomly assigned to receive one of several preservative-free lubricating eye drops, including Blink Triple Care and Systane variants, administered multiple times daily, such as four times daily QID or twice daily BID, depending on the specific product. The study treatment period lasts at least 14 days, during which participants will use the assigned eye drops according to the specified dosing schedule. Treatments are compared to assess comfort and symptom relief. During the study, participants will attend scheduled visits to assess dry eye symptoms using the Ocular Surface Disease Index OSDI over 14 days. They will be monitored for symptoms, tolerability, and visual function throughout the treatment period. Researchers will collect information on symptom relief and safety to understand the effects of the lubricating eye drops. Total participation and follow-up extend through the treatment period up to study completion.

Researchers are studying two experimental drugs, REGN5713 and REGN5715, to see if they can reduce eye allergy signs and symptoms caused by birch tree pollen allergy. This Phase 3 study compares how safe and effective these drugs are when given alone or together, versus a placebo. It also explores side effects, drug levels in the blood, and whether the body develops antibodies against the drugs that could affect their action or cause side effects. Participants will be randomly assigned to receive REGN5713 alone, REGN5715 alone, both drugs together, or a placebo. The study drugs are administered according to the study protocol. The trial uses a double-masked, placebo-controlled design to fairly compare the effects of these treatments on allergic conjunctivitis symptoms. The study includes a Conjunctival Allergen Challenge CAC to test drug effects at specific time points. During the study, participants will be monitored for eye itch and redness scores, nasal symptoms, and skin prick test changes. Blood samples will be taken to measure drug concentrations and antibody responses. Side effects and serious adverse events are carefully recorded up to Day 113. Assessments occur at baseline and multiple post-CAC time points, with the main outcome measured on Day 8. The study runs from January 2026 until June 2027, involving adolescent and adult participants aged 12 and older.